

# Financial Tear Sheet

## Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

## Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$3.77
Change (%)	0.00 (0.00%)
Volume	30,768
52 Week Low	\$2.88
Market Cap	\$77,924,121
Rolling EPS	-0.39
PE Ratio	0
Shares Outstanding	20,669,528
Data as of 08/17/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

July 25, 2018

**BRAINSTORM ANNOUNCES GRANT OF A NEW EUROPEAN PATENT FOR NUROWN®**

July 23, 2018

**BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018 AND PROVIDES A CORPORATE UPDATE**

July 17, 2018

**BRAINSTORM TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS OF 2018 AND PROVIDE A CORPORATE UPDATE ON MONDAY JULY 23**

## SEC Filings

Filing Date	Form
07/27/18	4
07/23/18	10-Q
06/29/18	EFFECT
06/29/18	S-3

## Upcoming Events

**BRAINSTORM CELL THERAPEUTICS - SECOND QUARTER 2018 EARNINGS CALL**

July 23, 2018 8:30 a.m. ET

## Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)